PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 72069

Complexing Rauscher leukemia virus reverse transcriptase with human plasma ribonuclease from Hodgkin's disease patients.

A K Bandyopadhyay·C C Levy·M R Mardiney
View original source ↗Export metadata ↓

Abstract

Human ribonucleases were purified from the sera of Hodgkin's disease patients by sequential column chromatography. The purified enzyme interacted with reverse transcriptase of Rauscher leukemia virus and formed an additive complex of Mr = 130,000. RNase and oligo(dG)-directed reverse transcriptase activities were diminished in the complex. The complex could be dissociated with the subsequent restoration of both activities in the presence of spermidine. The molecular weight of the complex suggest that the 2 RNase molecules bind to a single reverse transcriptase molecule.

Explore related subjects

Hodgkin DiseaseHumansMacromolecular SubstancesRNA-Directed DNA PolymeraseRauscher VirusRibonucleasesJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A K Bandyopadhyay, C C Levy, M R Mardiney. 1977-11-10. Complexing Rauscher leukemia virus reverse transcriptase with human plasma ribonuclease from Hodgkin's disease patients.. https://pubmed.ncbi.nlm.nih.gov/72069/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

The transcription factor NF-kappaB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-kappaB is required for the coordination of physiologic immune responses. However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies.

Hodgkin Disease↗